THE CHINWAGY BUZZ · FIRST VERIFIED WORD
Astellas and Vir Biotechnology advance a strategic prostate-cancer collaboration
WHAT CHINWAGY KNOWS
The collaboration
is confirmed.
Astellas describes its partnership with Vir Biotechnology to advance VIR-5500, a PSMA-targeting dual-masked T-cell engager, through clinical development for prostate cancer.
- Current status
- Official collaboration
- Known availability
- The official source confirms the collaboration; timing details remain under review.
- Place
- International, Global
- Source checked
- September 17, 2026
FOLLOW THE STORY